Research Projects & Grants

Federal

  • Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), Role: Investigational Pharmacist, National Institute of Allergy and Infectious Diseases/NIH/DHHS, Status: Completed

For Profit Organization

  • A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People >/= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection, Role: Investigational Pharmacist, Gilead Sciences, Inc, (07/2024 - 07/2025) Status: Approved
  • A Multicenter, Prospective, Open label, Randomized Controlled Clinical Trial to Compare the Safety and Effectiveness of the VitaSmart™ Liver Machine Perfusion System with Static Cold Storage for Organ Preservation Prior to Liver Transplantation BTL-2020-01 vs - Version 4.0 dated Sept. 23, 2021, Role: Investigator, Bridge to Life, Ltd, (12/2023 - 08/2024) Status: Completed
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter study to evaluate the safety and efficacy of Ravulizumab in Complement-Inhibitor-Naïve adult patients with Generalized Myasthenia Gravis: Protocol # ALXN1210-MG-306, Role: Investigator, Alexion Pharmaceuticals, (08/2022 - 08/2023) Status: Completed
  • A phase 4 randomized, active-comparator controlled clinical trial to study the safety of sugammadex (MK-8616) for the reversal of neuromuscular blockade induced by either rocuronlum bromide or vecuronium in American Society of Anesthesiologists (ASA) class 3 or 4 subjects. MK-8616-145-00, Role: Investigator, Merck, Sharp & Dohme Corp., (01/2019 - 01/2020) Status: Completed
  • Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017, Role: Investigator, Allergan Inc., (08/2018 - 08/2019) Status: Completed
  • A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patients, Role: Investigator, Novartis Pharmaceuticals Corporation, (10/2016 - 10/2017) Status: Completed
  • Pharmacokinetics of triferic (ferric pyrophosphate citrate) administered via dialysate and IV to pediatric patients on chronic hemodialysis, Role: Investigator, Rockwell Medical Inc., (10/2016 - 10/2017) Status: Completed
  • A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (Eisai, May 2015), Role: Investigator, Eisai Medical Research, Inc., (08/2016 - 08/2017) Status: Completed
  • A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation, Role: Investigator, Vertex Pharmaceuticals Incorporated (Vertex), (05/2014 - 05/2015) Status: Completed
  • A randomized, double-blind, active-controlled crossover study to evaluate the efficacy and safety of fentanyl buccal tablets compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain, followed by a 12-week open-label extension to evaluate the impact of fentanyl buccal tablets on patient outcomes (Protocol #C25608/3056/BP/US), Role: Investigator, Cephalon Inc., (11/2009 - 11/2010) Status: Completed
  • Botulism antitoxin effects on paralysis induced by type A and type B botulinum neurotoxins in the extensor digitorum brevis muscle. Protocol number BT-002, version 3.0, dated October 07, 2008. Investigator's brochure edition #4.0, dated 11/2007., Role: Investigator, Cangene Corporation, (10/2009 - 10/2010) Status: Completed
  • A randomized, double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the treatment of breakthrough cancer pain (INS-05-001), Role: Investigator, InSys Therapeutics, Inc., (08/2009 - 08/2010) Status: Completed
  • A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy (CP043/06/FCNS), Role: Investigator, Archimedes Development Ltd., (01/2009 - 01/2010) Status: Completed
  • An open-label, two-stage, phase II study to explore the titration schedule for transitioning opioid-experienced patients with non-malignant moderate to severe chronic pain from current opioid therapy to the sufentanil transdermal therapeutic system (#EN3270-201), Role: Investigator, Endo Pharmaceuticals, (06/2008 - 06/2009) Status: Completed
  • A randomized double-blind, placebo-controlled, two-way cross over study of analgesic efficacy of bupivacaine transdermal therapeutic system in patients with post-herpetic neuralgia, Role: Investigator, Durect Corporation, (09/2007 - 09/2008) Status: Completed
  • An open label, long term treatment evaluation of the safety of BEMATM fentanyl use for breakthrough pain in cancer subjects on chronic opioid therapy, Role: Investigator, BioDelivery Sciences International, Inc., (09/2007 - 09/2008) Status: Completed
  • A double-blind, randomized, placebo-controlled study of modafinil and morphine or oxycodone in patients with excessive daytime sleepiness due to opioid therapy, Role: Investigator, Medgenex, Inc., (03/2007 - 03/2008) Status: Completed
  • An open-label, long-term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe non-malignant chronic pain., Role: Investigator, ZARS, Inc., (07/2006 - 07/2007) Status: Completed
  • An open-label, long -term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe cancer pain., Role: Investigator, ZARS, Inc., (07/2005 - 07/2006) Status: Completed
  • A randomized, double-blind, placebo-controlled, multi-center study of the effects of ONO-2506 intravenous infusion on the amelioration of neurological damage and improvement of stroke assessment scale scores in patients with acute ischemic stroke Protocol #2506/INT0104:Version 1 Dated April 22, 2002: Clinical Investigators Brochure Edition #05 dated February 1, 2002: Amendment #1 dated July 17, 2002, Role: Investigator, ONO Pharmaceutical Co., Ltd., (05/2005 - 05/2006) Status: Completed
  • A multi-center, double-blind, randomized, active-controlled study to evaluate two formulations of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (9525X and 9060X) by measuring the compound muscle action potential (CMAP) of the Extensor Digitorum Brevis (EDB) muscle in response to a single intramuscular injection of varying doses in the EDB muscle of healthy volunteers (Protocol Number: 191622-051), Role: Investigator, Allergan Inc., (02/2005 - 02/2006) Status: Completed
  • A randomized, double-blind, parallel-design, placebo and active controlled, multicenter, ascending dose-ranging study of the safety and efficacy of single doses of Org 41793 in the treatment of post-operative pain in ASA Class I and II surgical inpatients. (Protocol No. 139-002, dated 08 August 2000), Role: Investigator, Organon USA Inc., (09/2000 - 09/2001) Status: Completed
  • A dose response study of the efficacy, safety and pharmacokinetics of intravenous amiodarone hydrochloride in pediatric patients 30 days of age to sixteen years of age with critical arrythmias, Role: Investigator, Wyeth-Ayerst Laboratories, Status: Completed

Internal

  • Understanding the Impact of Melatonin Use on Adolescent Functioning: A Pilot and Feasibility Trial of the Melatonin Adolescent Research Study (MARS), Role: Investigator, LLU Dept. of Psychology, (06/2024 - 06/2025) Status: Approved
  • A comparison of gingko biloba vs acetazolamide in the prevention of prevention of acute mountain sickness, Role: Investigator, LLU Dept. of Emergency Medicine, Status: Completed

Non-Profit Organization

  • Safety of furosemide in premature infants at risk of bronchopulmonary dysplasia (NICHD-2014-FUR01), Role: Investigator, Duke Clinical Research Institute, (07/2021 - 07/2022) Status: Completed
  • An open-label study in subjects with Parkinson's disease to evaluate the safety and tolerability of titration and continuous subcutaneous infusion of ABBV-951 for up to 4 weeks in an outpatient environment. Protocol: M15-739, Role: Investigator, AbbVie, Inc., (11/2019 - 11/2020) Status: Completed